- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00313768
Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC
September 24, 2009 updated by: Pfizer
A Randomized Phase 2 Trial Of Paclitaxel, Carboplatin And Bevacizumab With Or Without PF-3512676 As First-Line Treatment Of Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer
To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel, carboplatin and bevacizumab as first-line treatment in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
PF-3512676 dosing was stopped 21 June 2007 when Pfizer decided to stop the administration of PF-3512676 in all trials which combined PF-3512676 with cytotoxic chemotherapy.
the decision was made subsequent to DSMC recommendation to close two phase III randomized trials in non-small cell lung cancer which also combined PF-3512676 with cytotoxic chemotherapy, citing lack of efficacy concerns as the primary reason with safety issues (sepsis, thrombocytopenia) also contributing to the decision.
Subjects were allowed to complete standard of care treatment/survival follow-up.
Data collection was completed on 22 May 2008.
Study Type
Interventional
Enrollment (Actual)
23
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Bessemer, Alabama, United States, 35022
- Pfizer Investigational Site
-
Birmingham, Alabama, United States, 35209
- Pfizer Investigational Site
-
Birmingham, Alabama, United States, 35205
- Pfizer Investigational Site
-
Birmingham, Alabama, United States, 35213
- Pfizer Investigational Site
-
Birmingham, Alabama, United States, 35235
- Pfizer Investigational Site
-
Birmingham, Alabama, United States, 32511
- Pfizer Investigational Site
-
Mobile, Alabama, United States, 36607
- Pfizer Investigational Site
-
-
California
-
Fountain Valley, California, United States, 92708
- Pfizer Investigational Site
-
Los Angeles, California, United States, 90033
- Pfizer Investigational Site
-
-
Florida
-
Cocoa Beach, Florida, United States, 32931
- Pfizer Investigational Site
-
Merritt Island, Florida, United States, 32952
- Pfizer Investigational Site
-
Rockledge, Florida, United States, 32955
- Pfizer Investigational Site
-
Titusville, Florida, United States, 32796
- Pfizer Investigational Site
-
-
Georgia
-
Valdosta, Georgia, United States, 31602
- Pfizer Investigational Site
-
-
Illinois
-
Joliet, Illinois, United States, 60435
- Pfizer Investigational Site
-
Joliet, Illinois, United States, 60432
- Pfizer Investigational Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21231
- Pfizer Investigational Site
-
-
North Carolina
-
Clinton, North Carolina, United States, 28382
- Pfizer Investigational Site
-
Goldsboro, North Carolina, United States, 27534
- Pfizer Investigational Site
-
Pollocksville, North Carolina, United States, 28573
- Pfizer Investigational Site
-
Wilson, North Carolina, United States, 27893
- Pfizer Investigational Site
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37920
- Pfizer Investigational Site
-
Knoxville, Tennessee, United States, 37934
- Pfizer Investigational Site
-
-
Texas
-
Austin, Texas, United States, 78705
- Pfizer Investigational Site
-
Austin, Texas, United States, 78745
- Pfizer Investigational Site
-
Austin, Texas, United States, 78759
- Pfizer Investigational Site
-
Austin, Texas, United States, 78758
- Pfizer Investigational Site
-
Georgetown, Texas, United States, 78626
- Pfizer Investigational Site
-
San Marcos, Texas, United States, 78666
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Advanced Stage IIIb with pleural effusion or Stage IV nonsquamous non-small cell lung cancer
- ECOG Performance Status 0-1
- Measurable disease per RECIST criteria
Exclusion Criteria:
- Squamous cell, small cell, or carcinoid lung cancer
- CNS metastasis
- Pre-existing autoimmune or antibody mediated disease
- Prior systemic treatment for NSCLC with chemo, immunotherapy, biologics, or investigation drugs
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: B
Standard of care chemotherapy
|
paclitaxel 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles
Other Names:
|
Experimental: A
Standard of care chemotherapy plus experimental intervention (PF-3512676)
|
carboplatin AUC 6 intravenously on Day 1 of each 21 day cycle x 6 cycles
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression-free survival
Time Frame: 110 Events
|
110 Events
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Survival
Time Frame: Time of death
|
Time of death
|
Time to Tumor Progression
Time Frame: End of treatment
|
End of treatment
|
Overall Objective Response Rate
Time Frame: Time of progressive disease
|
Time of progressive disease
|
Duration of Response
Time Frame: Time of progression
|
Time of progression
|
Overall safety profile
Time Frame: 28 days post treatment
|
28 days post treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2005
Primary Completion (Actual)
May 1, 2008
Study Completion (Actual)
May 1, 2008
Study Registration Dates
First Submitted
April 10, 2006
First Submitted That Met QC Criteria
April 10, 2006
First Posted (Estimate)
April 12, 2006
Study Record Updates
Last Update Posted (Estimate)
September 28, 2009
Last Update Submitted That Met QC Criteria
September 24, 2009
Last Verified
September 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Carboplatin
- Paclitaxel
- Bevacizumab
- Albumin-Bound Paclitaxel
Other Study ID Numbers
- A8501003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Non-Small-Cell Lung
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingLung Non-Squamous Non-Small Cell Carcinoma | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7United States, Puerto Rico
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IA...United States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage I Lung Non-Small Cell Cancer AJCC v7 | Stage...United States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingStage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Society of Thoracic RadiologyActive, not recruitingStage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
Clinical Trials on paclitaxel + carboplatin + bevacizumab
-
Innovent Biologics (Suzhou) Co. Ltd.WuXi CDS Clinical Research (Shanghai) Co.Ltd.Completed
-
Spanish Lung Cancer GroupCompletedNonsquamous Nonsmall Cell Neoplasm of LungSpain
-
Jiangsu HengRui Medicine Co., Ltd.CompletedNon-small Cell Lung Cancer(NSCLC)China
-
Genentech, Inc.Completed
-
Grupo de Investigación y Divulgación OncológicaUnknownNon-small Cell Lung Cancer (NSCLC)Spain
-
Guangzhou Gloria Biosciences Co., Ltd.Not yet recruitingPersistent, Recurrent, or Metastatic Cervical CancerChina
-
Northwestern UniversityNational Cancer Institute (NCI)Terminated
-
Genentech, Inc.Completed
-
The Cleveland ClinicGenentech, Inc.CompletedEndometrial CarcinomaUnited States
-
Genentech, Inc.CompletedNon-Squamous Non-Small Cell Lung CancerAustralia, United States, Hungary, France, Germany, Czech Republic, Poland